New York Genome Center and Sohn Conference Foundation Collaborate on Pediatric Cancer Research - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

New York Genome Center and Sohn Conference Foundation Collaborate on Pediatric Cancer Research


The New York Genome Center (NYGC) and The Sohn Conference Foundation launched The Sohn Collaborative for Pediatric Cancer Research, a multi-institutional effort with the goal of fighting two childhood cancers: pediatric leukemia and neuroblastoma. NYGC will act as a nexus and participant in this research collaborative with five of its Institutional Founding Members: Columbia University, Memorial Sloan Kettering Cancer Center, New York University School of Medicine, The Rockefeller University, and Weill Cornell Medical College. NYGC will also conduct the genome sequencing and computational analysis for this synergistic research endeavor.

The Sohn Conference Foundation’s grant empowers these institutions to harness their collective knowledge and technology to apply genomic science to identify and analyze why some children’s tumors respond readily to treatment, while other patients suffer relapses or have no response at all. While leukemia and neuroblastoma are different—leukemia affects blood and neuroblastoma is the commonest childhood solid tumor—researchers will pursue a similar approach to understand them. Sequencing the genomes of “outlier” tumors, those that have unusual responses to treatment, either good or bad, may yield valuable clues on how to fight these cancers more effectively

Source: The New York Genome Center

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here